B-Cell Malignancies
Conditions
Brief summary
This is a multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.
Detailed description
The study will consist of two parts, dose escalation and dose expansion. A modified 3+3 design will be used to guide the dose escalation and the determination of the dose recommended for dose expansion (DRDE). A sentinel cohort comprising of one subject will be enrolled at a starting dose of 50 mg q.d. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design to determine the DRDE. Once the DRDE has been selected, TT-01488 of DRDE will be further tested in the dose expansion cohort to verify the safety and preliminary efficacy as observed in the dose escalation cohorts. A recommended Phase II dose (RP2D) may be determined based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation cohorts and dose expansion cohort.
Interventions
DRUGTT-01488 Tablets
TT-01488 tablet will be administered orally once daily per protocol defined schedule.
Sponsors
TransThera Sciences (Nanjing), Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants with histologically confirmed B-cell malignancy, failed or intolerant to either ≥ 2 prior standard/common regimens given in combination or sequentially OR have received 1 prior BTK-containing regimen, relapse/refractory, and with treatment indication: * CLL/SLL treated with prior immunochemistry or BTK inhibitor containing regimen; * DLBCL treated with prior CD20 or anthracyclines containing regimen; * Other types of B-cell NHL treated with prior CD20 containing regimen * Adequate organ function, defined by the following laboratory parameters: * Hematologic: * Absolute neutrophil count (ANC) ≥ 0.75×10\^9/L, and ≥ 0.5×10\^9/L if bone marrow involved * Platelets ≥ 50×10\^9/L without transfusion within 7 days, and ≥ 30×10\^9/L if bone marrow involved * Hemoglobin ≥ 8.0 g/dL without transfusion within 7 days, and ≥ 7.0 g/dL if bone marrow involved * Coagulation: * Prothrombin time (PT) ≤ 1.5 × ULN * Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN * Renal function: * Creatinine clearance ≥ 30 mL/min estimated glomerular filtration rate based on Cockcroft-Gault formula * Liver function: * Total bilirubin ≤ 1.5 × ULN (unless due to Gilbert's disease) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN unless disease-related
Exclusion criteria
* Women who are pregnant or lactating * Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years or which will not limit survival to \< 2 years (Note: these cases must be discussed with the Medical Monitor and/or Investigator) * Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or significant screening ECG abnormalities * Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction * History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days or with any of the following: * Active graft versus host disease (GvHD); * Cytopenias from incomplete blood cell count recovery post-transplant; * Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity \> Grade 1 from CAR-T therapy; * Ongoing immunosuppressive therapy * Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-Limiting Toxicity (DLT) of TT-01488 | Up to 28 days after first dose | Safety and tolerability of TT-01488 as a single agent |
| Dose recommend for dose expansion (DRDE) | 3 years | Safety and tolerability of TT-01488 as a single agent |
| Maximum Tolerated Dose (MTD), if reached, of TT-01488 | Up to 28 days after first dose | Safety and tolerability of TT-01488 as a single agent |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 3 years | Pharmacokinetic (PK) profile of TT-01488 as a single agent |
| Half-life (T1/2) | 3 years | Pharmacokinetic (PK) profile of TT-01488 as a single agent |
| Mean Residence Time (MRT) | 3 years | Pharmacokinetic (PK) profile of TT-01488 as a single agent |
| Apparent volume of distribution associated with the terminal phase (Vz/F) | 3 years | Pharmacokinetic (PK) profile of TT-01488 as a single agent |
| Apparent clearance (CL/F) | 3 years | Pharmacokinetic (PK) profile of TT-01488 as a single agent |
| Number of participants with treatment-related adverse events (AEs) | 3 years | Safety and tolerability of TT-01488 as a single agent. AEs will be assessed per CTCAE v5.0 or 2018 IWCLL and may include, but is not limited to, clinically abnormal laboratory tests, physical exams, vital signs, electrocardiograms, and ECOG performance status. |
| Disease Control Rate (DCR) | 3 years | Preliminary efficacy profile of TT-01488 as a single agent |
| Duration of Response (DOR) | 3 years | Preliminary efficacy profile of TT-01488 as a single agent |
| Progression free survival (PFS) | 3 years | Preliminary efficacy profile of TT-01488 as a single agent |
| Overall survival (OS) | 3 years | Preliminary efficacy profile of TT-01488 as a single agent |
| Objective Response Rate (ORR) | 3 years | Preliminary efficacy profile of TT-01488 as a single agent |
| Area under the concentration time curve (AUC 0-t) | 3 years | Pharmacokinetic (PK) profile of TT-01488 as a single agent |
| Maximum plasma concentration (Cmax) | 3 years | Pharmacokinetic (PK) profile of TT-01488 as a single agent |
Countries
China
Contacts
Primary ContactSun Caixia, PhD
Outcome results
None listed